Mink Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Mink Therapeutics

03/11/2022 14:26

* Mink Therapeutics Inc  INKT.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 23 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Mink Therapeutics Inc's reported EPS for the quarter was a
loss
of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Mink Therapeutics Inc shares had risen by 0.9% this
quarter and
lost 52.2% so far this year.
    * The company reported a quarterly loss of $6.33 million.
    * Wall Street's median 12-month price target for Mink
Therapeutics
Inc is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 02:26 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.23          -0.19          Beat
 Jun. 30 2022      -0.24          -0.18          Beat
 Mar. 31 2022      -0.21          -0.23          Missed
 Dec. 31 2021      -0.41          -0.18          Beat